Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.67 |
| ▸ | GRM6 | O15303 | 2/20 | 0.67 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.67 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.67 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.67 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.67 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.67 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.67 |
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.67 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.67 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9309394 | 1.00 | GRM8 (0.67) | GRM8GRM6GRM7GRM4GRIK1 | |
| SCHEMBL2859864 | 0.85 | ENPEP (0.60) | GRM8GRM6GRM7GRM4GRIK1 | |
| SCHEMBL28267787 | 0.82 | GRM8 (0.67) | GRM8GRM6GRM7GRM4GRIK1 | |
| SCHEMBL27399381 | 0.81 | GGT1 (0.54) | GRM8GRM6GRM7GRM4GRIK1 | |
| D-Glutamate SCHEMBL410241 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 | |
| D-Glutamate SCHEMBL1330824 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 | |
| D-Glutamate SCHEMBL1330484 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 | |
| D-Glutamate SCHEMBL2201 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 | |
| D-Glutamate SCHEMBL17127348 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 | |
| Glutamic Acid SCHEMBL1554237 | 0.80 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-8846053-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | GRM8 3134/4885GRM6 2240/4885GRM7 2915/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | GRM8 2828/4885GRM6 791/4885GRM7 2159/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | GRM8 2617/4885GRM6 1703/4885GRM7 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.